ASTH: Rounding Bottom detected on 19 May 2026

ASTH has formed a rounding bottom pattern with solid structural integrity (15/15 score). The stock is trading at $38.98, approximately 2.4% below its 52-week high of $39.80, having recovered 115.6% from the 52-week low of $18.08. Key support lies at $18.08 with resistance at $31.96. The conservative breakout target is $40.67. Volume scores 10/10, though current volume (491,740 shares) sits at 0.97x the 20-day average, indicating modest trading intensity. The breakout score of 7/13 suggests moderate technical confirmation potential. Overall pattern quality: 65/98, with a 60.84% win probability.

Astrana Health reported Q1 2026 revenue of $965.1 million (up 56% YoY) and net income of $14.4 million, driven by its value-based care model and the 2025 Prospect acquisition. The company delivered EPS of $0.74, far exceeding the forecasted $0.29, marking a 155.17% surprise. On the earnings announcement day (May 7), ASTH gained 8.92%, with a peak intraday move of +20.7%. Management reaffirmed full-year 2026 guidance for revenue of $3.8B–$4.1B, adjusted EBITDA of $250M–$280M, and free cash flow of $105M–$132.5M. Analysts maintain a bullish consensus "Buy" rating with price targets ranging from $26 to $50. The rounding bottom is forming post-earnings in a favorable fundamental backdrop of strong growth and operational leverage.

A successful breakout above resistance at $31.96 would confirm the rounding bottom completion, with the conservative measured move target at $40.67—a gain of approximately 4.3% from current price. The pattern suggests buyers should watch for volume expansion on any move above resistance; current volume is tracking near average, so breakout confirmation would ideally include a volume spike above the 20-day mean of 505,863 shares. The setup invalidates below the key support level of $18.08. With a 60.84% win probability, historical backtests suggest this structure is moderately reliable. The technical setup aligns with the bullish market regime (0.85 score), though Consumer Discretionary sector headwinds (-0.4 regime score) represent a structural headwind.

ASTH trades at an RSI of 70.89, indicating overbought conditions that increase near-term correction risk. Customer concentration is material: one major payer accounted for 20.9% of Q1 2026 revenue and 39.2% of receivables, creating exposure to contract or payment changes. Total debt stands at $1.04 billion with quarterly interest expense of $16.1 million, reflecting reliance on acquisition financing. Beta is low at 0.42, but 20-day volatility is elevated at 44.4%, suggesting price swings could disrupt the pattern. The Consumer Discretionary sector trades in bearish regime (-0.4), which may weigh on healthcare service names. No near-term earnings catalyst exists beyond Q2 guidance, reducing catalytic support for sustained breakout momentum.